Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07799077 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Name: Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma — clinical trial record (NCT07799077)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorHebei Medical University Fourth Hospital

Started2026-09-01

View on ClinicalTrials.gov ↗

Hebei Medical University Fourth Hospital

53 trials monitored

See 1 trial at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

Locally advanced Esophageal Squamous Cell Carcinoma (ESCC) has poor prognosis with standard therapies. Neoadjuvant immunochemotherapy improves pathological response rates, but optimal regimens remain undefined. Paclitaxel polymeric micelles offer enhanced tumor targeting (EPR effect) and reduced toxicity vs. conventional paclitaxel formulations, with no need for premedication. This single-arm, prospective trial evaluates the efficacy and safety of neoadjuvant sintilimab combined with paclitaxel polymeric micelles and cisplatin in resectable locally advanced ESCC.

Trial Details

NCT Number	NCT07799077
Lead Sponsor	Hebei Medical University Fourth Hospital Collaborators: Shanghai Yizhong Pharmaceutical Co., Ltd.
Conditions	Esophageal Squamous Cell Carcinoma
Enrollment	32 participants
Start Date	2026-09-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-02